Real-world effectiveness of MD1003 (high dose pharmaceutical grade biotin) in patients with progressive MS

被引：0
|
作者：
Faure, J.
Jauffret, J.
Carreau, C. [1 ,2 ]
Legrain, P. [1 ,2 ]
Castex, C. [1 ]
Tourbah, A.
机构：
[1] CHU Reims, Reims, France
[2] Univ Reims, Reims, France
来源：
MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P585
引用
收藏
页码：281 / 282
页数：2
相关论文
共 50 条
  • [41] Improvement in the composite endpoint of timed 25 foot walk, maximum walking distance, or EDSS in a cohort of patients from the MD1003 (high dose pharmaceutical-grade biotin) in the French Early Access Program
    Tourbah, A.
    Faure, J.
    Carreau, C.
    Legrain, P.
    Castex, C.
    Caucheteux, N.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 530 - 530
  • [42] MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study
    Ayman Tourbah
    Olivier Gout
    Alain Vighetto
    Véronique Deburghgraeve
    Jean Pelletier
    Caroline Papeix
    Christine Lebrun-Frenay
    Pierre Labauge
    David Brassat
    Ahmed Toosy
    David-Axel Laplaud
    Olivier Outteryck
    Thibault Moreau
    Marc Debouverie
    Pierre Clavelou
    Olivier Heinzlef
    Jérôme De Sèze
    Gilles Defer
    Frédéric Sedel
    Carl Arndt
    [J]. CNS Drugs, 2018, 32 : 661 - 672
  • [43] MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study
    Tourbah, Ayman
    Gout, Olivier
    Vighetto, Alain
    Deburghgraeve, Veronique
    Pelletier, Jean
    Papeix, Caroline
    Lebrun-Frenay, Christine
    Labauge, Pierre
    Brassat, David
    Toosy, Ahmed
    Laplaud, David-Axel
    Outteryck, Olivier
    Moreau, Thibault
    Debouverie, Marc
    Clavelou, Pierre
    Heinzlef, Olivier
    De Seze, Jerme
    Defer, Gilles
    Sedel, Frederic
    Arndt, Carl
    [J]. CNS DRUGS, 2018, 32 (07) : 661 - 672
  • [44] Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial
    Cree, Bruce A. C.
    Cutter, Gary
    Wolinsky, Jerry S.
    Freedman, Mark S.
    Comi, Giancarlo
    Giovannoni, Gavin
    Hartung, Hans-Peter
    Arnold, Douglas
    Kuhle, Jens
    Block, Valerie
    Munschauer, Frederick E.
    Sedel, Frederic
    Lublin, Fred D.
    [J]. LANCET NEUROLOGY, 2020, 19 (12): : 988 - 997
  • [45] Effect of MD1003 (high doses of Biotin) in progressive multiple sclerosis: results of a pivotal phase III randomised double-blind placebo controlled study
    Tourbah, A.
    Lebrun-Frenay, C.
    Edan, G.
    Clanet, M.
    Papeix, A. -C.
    Vukusic, S.
    de Seze, J.
    Debouverie, M.
    Gout, O.
    Clavelou, P.
    Defer, G. L.
    Laplaud, D.
    Moreau, T.
    Labauge, P.
    Brochet, B.
    Sedel, M. M. F.
    Pelletier, J.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 49 - 49
  • [46] Remotely Monitored Ambulatory Activity Correlates With Disability In Progressive MS: Baseline Data From The SPI2 Ph3 Trial Of Md1003 (hdpb Biotin)
    Block, V. J.
    Alexander, A. M.
    Papinutto, N.
    Rajesh, A.
    Gundel, T.
    Gelfand, J. M.
    Henry, R.
    Sedel, F.
    Cree, B. A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 34 - 35
  • [47] Effect of MD1003 (High Doses of Biotin) in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis (MS-ON): Results of a Pivotal Randomized Double Masked Placebo Controlled Study
    Tourbah, Ayman
    Arndt, Carl
    Vighetto, Alain
    Deburghgraeve, Veronigue
    Pelletier, Jean
    Papeix, Caroline
    Lebrun-Frenay, Christine
    Labauge, Pierre
    Clanet, Michel
    Toosy, Ahmed
    Laplaud, David
    Vermersch, Patrick
    Moreau, Thibault
    Debouverie, Marc
    Clavelou, Pierre
    Heinzlel, Olivier
    De Seze, Jerome
    Defer, Gilles
    Sedel, Frederic
    Gout, Olivier
    [J]. NEUROLOGY, 2016, 86
  • [48] Ocrelizumab treatment in patients with relapsing-remitting and progressive MS: a real-world experience
    Cellerino, M.
    Boffa, G.
    Lapucci, C.
    Tazza, F.
    Sbragia, E.
    Mancuso, E.
    Bruschi, N.
    Poire, I.
    Minguzzi, S.
    Tregrosso, A.
    Laroni, A.
    Capello, E.
    Mancardi, G.
    Uccelli, A.
    Novi, G.
    Inglese, M.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 91 - 91
  • [49] 24-Month-Treatment with-MD1003 (High Doses of Biotin) in Progressive Multiple Sclerosis: Results of the MS-SPI Trial Extension Phase
    Tourbah, Ayman
    Lebrun-Frenay, Christine
    Edan, Gilles
    Clane, Michel
    Papeix, Caroline
    Vukusic, Sandra
    De Seze, Jerome
    Debouverie, Marc
    Gout, Olivier
    Clavelou, Pierre
    Defer, Gilles
    Laplaud, David
    Moreau, Thibault
    Labauge, Pierre
    Brochet, Bruno
    Sedel, Frederic
    Pelletier, Jean
    [J]. NEUROLOGY, 2016, 86
  • [50] REAL-WORLD EXPERIENCE WITH TEMOZOLOMIDE & SATIVEX IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMAS
    Shahabi, Lillie
    Le Calvez, Kerlann
    Dadhania, Seema
    Blake, Catherine
    Wang, James
    Ingle, Manasi
    Anichini, Giulio
    Peterson, David
    Nandi, Dipankar
    Camp, Sophie
    Saleem, Waqar
    Falconer, Alison
    O'Neill, Kevin
    Williams, Matt
    [J]. NEURO-ONCOLOGY, 2019, 21 : 13 - 14
12345